Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AA Alcoa	$48.78 +0.6%	$63.55	$28.11 ▼ $84.38	$12.80B	1.63	6.50 million shs	5.04 million shs
HIMS Hims & Hers Health	$35.53 -1.5%	$29.21	$13.74 ▼ $70.43	$8.35B	2.35	16.41 million shs	8.99 million shs
LLY Eli Lilly and Company	$1,215.41 0.0%	$1,091.91	$623.78 ▼ $1,249.45	$1.14T	0.51	2.93 million shs	2.09 million shs
LRN Stride	$91.06 +1.3%	$90.60	$60.61 ▼ $171.17	$3.82B	0.1	875,106 shs	541,219 shs
NVDA NVIDIA	$202.78 -0.7%	$209.45	$161.61 ▼ $236.54	$4.94T	2.21	132.88 million shs	131.28 million shs
NVO Novo Nordisk A/S	$48.93 +0.1%	$45.39	$35.12 ▼ $71.79	$218.29B	0.77	11.06 million shs	5.41 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AA Alcoa	+0.66%	+0.25%	-32.69%	-33.19%	+59.11%
HIMS Hims & Hers Health	-1.41%	-3.31%	+22.46%	+82.67%	-30.52%
LLY Eli Lilly and Company	-0.27%	+0.58%	+6.31%	+29.33%	+54.44%
LRN Stride	+1.02%	+0.89%	-6.29%	+0.77%	-33.15%
NVDA NVIDIA	-0.66%	+4.08%	-2.60%	+7.48%	+24.50%
NVO Novo Nordisk A/S	+0.14%	-2.89%	+15.91%	+30.43%	-29.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AA Alcoa	$48.78 +0.6%	$63.55	$28.11 ▼ $84.38	$12.80B	1.63	6.50 million shs	5.04 million shs
HIMS Hims & Hers Health	$35.53 -1.5%	$29.21	$13.74 ▼ $70.43	$8.35B	2.35	16.41 million shs	8.99 million shs
LLY Eli Lilly and Company	$1,215.41 0.0%	$1,091.91	$623.78 ▼ $1,249.45	$1.14T	0.51	2.93 million shs	2.09 million shs
LRN Stride	$91.06 +1.3%	$90.60	$60.61 ▼ $171.17	$3.82B	0.1	875,106 shs	541,219 shs
NVDA NVIDIA	$202.78 -0.7%	$209.45	$161.61 ▼ $236.54	$4.94T	2.21	132.88 million shs	131.28 million shs
NVO Novo Nordisk A/S	$48.93 +0.1%	$45.39	$35.12 ▼ $71.79	$218.29B	0.77	11.06 million shs	5.41 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AA Alcoa	+0.66%	+0.25%	-32.69%	-33.19%	+59.11%
HIMS Hims & Hers Health	-1.41%	-3.31%	+22.46%	+82.67%	-30.52%
LLY Eli Lilly and Company	-0.27%	+0.58%	+6.31%	+29.33%	+54.44%
LRN Stride	+1.02%	+0.89%	-6.29%	+0.77%	-33.15%
NVDA NVIDIA	-0.66%	+4.08%	-2.60%	+7.48%	+24.50%
NVO Novo Nordisk A/S	+0.14%	-2.89%	+15.91%	+30.43%	-29.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AA Alcoa	2.27	Hold	$64.91	33.05% Upside
HIMS Hims & Hers Health	2.13	Hold	$30.70	-13.60% Downside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,260.33	3.70% Upside
LRN Stride	2.43	Hold	$109.75	20.53% Upside
NVDA NVIDIA	3.00	Buy	$303.84	49.84% Upside
NVO Novo Nordisk A/S	2.17	Hold	$65.56	33.99% Upside

Current Analyst Ratings Breakdown

Latest HIMS, NVO, LLY, AA, NVDA, and LRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2026	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1,370.00
7/9/2026	AA Alcoa	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$70.00 ➝ $55.00
7/9/2026	AA Alcoa	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underperform	$57.00 ➝ $51.00
7/9/2026	AA Alcoa	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$71.00 ➝ $72.00
7/9/2026	HIMS Hims & Hers Health	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$36.00 ➝ $37.00
7/8/2026	LRN Stride	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/8/2026	NVDA NVIDIA	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B)
7/8/2026	LLY Eli Lilly and Company	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,281.00 ➝ $1,370.00
7/8/2026	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,344.00 ➝ $1,347.00
7/8/2026	AA Alcoa	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/8/2026	AA Alcoa	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$79.00 ➝ $53.00

(Data available from 7/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AA Alcoa	$12.83B	1.00	$6.86 per share	7.11	$23.62 per share	2.07
HIMS Hims & Hers Health	$2.35B	3.50	$0.82 per share	43.10	$2.38 per share	14.93
LLY Eli Lilly and Company	$65.18B	17.56	$25.13 per share	48.37	$28.07 per share	43.30
LRN Stride	$2.41B	1.61	$11.38 per share	8.00	$34.00 per share	2.68
NVDA NVIDIA	$215.94B	22.73	$4.69 per share	43.21	$6.47 per share	31.34
NVO Novo Nordisk A/S	$46.80B	4.67	$4.69 per share	10.43	$6.58 per share	7.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AA Alcoa	$1.16B	$3.95	12.35	6.43	0.70	8.27%	12.57%	5.05%	7/16/2026 (Confirmed)
HIMS Hims & Hers Health	$128.37M	-$0.09	N/A	68.33	101.51	-0.56%	6.10%	1.52%	8/10/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	43.18	27.09	1.51	34.98%	105.77%	23.76%	8/5/2026 (Estimated)
LRN Stride	$287.94M	$6.48	14.05	10.20	0.50	12.15%	25.20%	16.65%	8/4/2026 (Estimated)
NVDA NVIDIA	$120.07B	$6.53	31.05	17.08	0.45	62.97%	96.94%	72.16%	8/26/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.26	11.49	14.96	4.46	37.23%	63.31%	22.19%	8/5/2026 (Estimated)

Latest HIMS, NVO, LLY, AA, NVDA, and LRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$8.80	N/A	N/A	N/A	$20.55 billion	N/A
8/5/2026	Q2 2026	NVO Novo Nordisk A/S	$0.82	N/A	N/A	N/A	$10.97 billion	N/A
8/4/2026	Q4 2026	LRN Stride	$1.61	N/A	N/A	N/A	$626.26 million	N/A
7/16/2026	Q2 2026	AA Alcoa	$2.29	N/A	N/A	N/A	$3.98 billion	N/A
5/20/2026	Q1 2027	NVDA NVIDIA	$1.76	$1.87	+$0.11	$2.39	$78.42 billion	$81.62 billion
5/11/2026	Q1 2026	HIMS Hims & Hers Health	$0.04	-$0.40	-$0.44	-$0.40	$616.84 million	$608.10 million
5/6/2026	Q1 2026	NVO Novo Nordisk A/S	$0.87	$1.04	+$0.17	$1.69	$10.86 billion	$10.85 billion
4/30/2026	Q1 2026	LLY Eli Lilly and Company	$6.97	$8.55	+$1.58	$8.26	$17.82 billion	$19.80 billion
4/28/2026	Q3 2026	LRN Stride	$2.21	$2.30	+$0.09	$1.93	$629.69 million	$629.87 million
4/16/2026	Q1 2026	AA Alcoa	$1.60	$1.40	-$0.20	$1.60	$3.35 billion	$3.19 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AA Alcoa	$0.40	0.82%	N/A	10.13%	N/A
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.92	0.57%	+15.18%	24.58%	11 Years
LRN Stride	N/A	N/A	N/A	N/A	N/A
NVDA NVIDIA	$1.00	0.49%	+14.87%	15.31%	1 Years
NVO Novo Nordisk A/S	$1.75	3.58%	+21.74%	41.08%	N/A

Latest HIMS, NVO, LLY, AA, NVDA, and LRN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.63%	8/14/2026	8/14/2026	9/10/2026
5/20/2026	NVDA NVIDIA	quarterly	$0.25	0.46%	6/4/2026	6/4/2026	6/26/2026
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.69%	5/15/2026	5/15/2026	6/10/2026
5/7/2026	AA Alcoa	quarterly	$0.10	0.63%	5/19/2026	5/19/2026	6/5/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AA Alcoa	0.36	1.48	0.88
HIMS Hims & Hers Health	2.18	1.69	1.56
LLY Eli Lilly and Company	1.26	1.50	1.10
LRN Stride	0.29	6.21	6.14
NVDA NVIDIA	0.04	3.44	2.85
NVO Novo Nordisk A/S	0.59	0.79	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AA Alcoa	N/A
HIMS Hims & Hers Health	63.52%
LLY Eli Lilly and Company	82.53%
LRN Stride	98.24%
NVDA NVIDIA	65.27%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
AA Alcoa	N/A
HIMS Hims & Hers Health	11.76%
LLY Eli Lilly and Company	0.14%
LRN Stride	3.00%
NVDA NVIDIA	3.94%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AA Alcoa	14,900	263.89 million	N/A	Optionable
HIMS Hims & Hers Health	2,442	231.46 million	204.24 million	Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
LRN Stride	8,600	42.53 million	41.25 million	Optionable
NVDA NVIDIA	42,000	24.20 billion	23.25 billion	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable

HIMS, NVO, LLY, AA, NVDA, and LRN Headlines

Recent News About These Companies

Azzad Asset Management Inc. ADV Has $3.61 Million Holdings in Novo Nordisk A/S $NVO

3 hours ago | marketbeat.com

Novo Nordisk (NVO) In Focus After Wegovy Label Update As Undervalued Narrative Holds

July 9 at 7:15 PM | finance.yahoo.com

Exclusive: Novo Nordisk Launches World's First Once-Weekly Insulin In India

July 9 at 2:14 PM | ndtv.comN

Novo Nordisk launches world's first once-weekly basal insulin in India: What it means for diabetes care

July 9 at 2:14 PM | msn.com

3 High Growth GLP-1 Biotech Winners to Buy in July

July 9 at 8:00 AM | 247wallst.com

Novo Nordisk: Why I Don't Think The Story Is Broken

July 9 at 8:00 AM | seekingalpha.com

Capstone Capital Management Ltd Purchases Shares of 25,434 Novo Nordisk A/S $NVO

July 9 at 3:51 AM | marketbeat.com

Novo Nordisk launches weekly insulin Awiqli in India as diabetes burden rises

July 9 at 2:23 AM | reuters.com

Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know

July 8 at 11:11 PM | finance.yahoo.com

GLP-1 weight-loss drug popularity reaches new heights with Americans

July 8 at 11:11 PM | thestreet.com

Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know

July 8 at 6:46 PM | zacks.com

Leading bank backs European pharma as the cleaner alternative to the AI trade

July 8 at 1:10 PM | proactiveinvestors.com

LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now?

July 8 at 1:10 PM | finance.yahoo.com

Novo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdown

July 8 at 1:10 PM | proactiveinvestors.com

Novo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdown

July 8 at 10:39 AM | proactiveinvestors.co.uk

As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner (NVO)

...

July 8 at 9:45 AM | marketbeat.com

MAHE and Novo Nordisk GBS expand collaboration in pharmacometrics

July 8 at 8:09 AM | thehindubusinessline.com

Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant

July 8 at 8:09 AM | pharmaceutical-technology.comP

Leading bank backs European pharma as the cleaner alternative to the AI trade

July 8 at 8:08 AM | proactiveinvestors.co.uk

3 Reasons to Buy Novo Nordisk Stock

July 7 at 5:06 PM | fool.com

Novo Nordisk Loses Its Edge, And I'm Downgrading

July 7 at 2:24 PM | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HIMS, NVO, LLY, AA, NVDA, and LRN Company Descriptions

Alcoa NYSE:AA

$48.78 +0.27 (+0.56%)

Closing price 07/9/2026 03:59 PM Eastern

Extended Trading

$48.90 +0.12 (+0.24%)

As of 06:30 AM Eastern

Alcoa Corporation, together with its subsidiaries, produces and sells bauxite, alumina, and aluminum products in the United States, Spain, Australia, Iceland, Norway, Brazil, Canada, and internationally. The company operates through two segments, Alumina and Aluminum. It engages in bauxite mining operations; and processes bauxite into alumina and sells it to customers who process it into industrial chemical products, as well as aluminum smelting and casting businesses. The company offers primary aluminum in the form of alloy ingot or value-add ingot to customers that produce products for the transportation, building and construction, packaging, wire, and other industrial markets; and flat-rolled aluminum in the form of sheet, which is sold primarily to customers that produce beverage and food cans. In addition, it owns hydro power plants that generates and sells electricity in the wholesale market to traders, large industrial consumers, distribution companies, and other generation companies. The company was formerly known as Alcoa Upstream Corporation and changed its name to Alcoa Corporation in October 2016. The company was founded in 1886 and is headquartered in Pittsburgh, Pennsylvania.

Hims & Hers Health NYSE:HIMS

$35.53 -0.54 (-1.49%)

Closing price 07/9/2026 03:59 PM Eastern

Extended Trading

$35.68 +0.15 (+0.43%)

As of 06:37 AM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company NYSE:LLY

$1,215.41 -0.42 (-0.03%)

Closing price 07/9/2026 03:59 PM Eastern

Extended Trading

$1,225.94 +10.53 (+0.87%)

As of 06:37 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Stride NYSE:LRN

$91.06 +1.18 (+1.31%)

Closing price 07/9/2026 03:59 PM Eastern

Extended Trading

$90.46 -0.60 (-0.66%)

As of 05:08 AM Eastern

Stride, Inc., a technology-based education service company, engages in the provision of proprietary and third-party online curriculum, software systems, and educational services in the United States and internationally. Its technology-based products and services enable clients to attract, enroll, educate, track progress, support, and facilitate individualized learning for students. The company offers integrated package of systems, services, products, and professional expertise to support a virtual or blended public school; software and services to schools and school districts; individual online courses and supplemental educational products; and products and services for the general education market focused on subjects, including math, English, science, and history for kindergarten through twelfth grade students. It also provides career learning products and services that are focused on developing skills to enter in industries, including information technology, health care, and business; and operates tuition-based private schools. In addition, the company offers focused post-secondary career learning programs, which include skills training for software engineering, healthcare, and medical fields to adult learners under Galvanize, Tech Elevator, and MedCerts brand names, as well as provides staffing and talent development services to employers. It serves public and private schools, school districts, charter boards, consumers, employers, and government agencies. The company was formerly known as K12 Inc. and changed its name to Stride, Inc. in December 2020. Stride, Inc. was incorporated in 1999 and is headquartered in Reston, Virginia.

NVIDIA NASDAQ:NVDA

$202.78 -1.34 (-0.66%)

Closing price 07/9/2026 04:00 PM Eastern

Extended Trading

$201.97 -0.81 (-0.40%)

As of 06:38 AM Eastern

NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.

Novo Nordisk A/S NYSE:NVO

$48.93 +0.04 (+0.09%)

Closing price 07/9/2026 03:59 PM Eastern

Extended Trading

$49.32 +0.39 (+0.79%)

As of 06:37 AM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HIMS, NVO, LLY, AA, NVDA, and LRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HIMS, NVO, LLY, AA, NVDA, and LRN Earnings

Compare Dividends

Latest HIMS, NVO, LLY, AA, NVDA, and LRN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HIMS, NVO, LLY, AA, NVDA, and LRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HIMS, NVO, LLY, AA, NVDA, and LRN Company Descriptions

Alcoa NYSE:AA

Hims & Hers Health NYSE:HIMS

Eli Lilly and Company NYSE:LLY

Stride NYSE:LRN

NVIDIA NASDAQ:NVDA

Novo Nordisk A/S NYSE:NVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools